ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements with these filters
Syngene International Limited announced the resignation of Mr. Pramuch Goel, Head of Corporate Affairs & Communications and Senior Management Personnel, effective September 21, 2026.
Syngene International Limited has issued a communication to shareholders regarding the remittance of the final dividend for the financial year 2025-26.
Syngene International has granted 14,26,061 Performance Share Units (PSUs) to eligible employees under the company's 2023 Long Term Incentive Performance Share Plan.
Syngene International Limited is investing ₹2.52 Crore to acquire a 12.44% equity stake in Ampin C&I Power Twelve Private Limited for renewable energy power consumption.
Syngene reports Q1 FY27 revenue of Rs 736 Cr (-16% YoY). Performance was impacted by low offtake from a major client and forex losses.
Syngene International Limited held its 33rd Annual General Meeting on July 29, 2026. The meeting transacted business including the adoption of financial statements and dividend declaration.
Independent Director Mr. Kush Parmar resigned from Syngene International, effective July 29, 2026, due to overseas commitments. He also vacated his board committee memberships.
Syngene International Ltd announced its Q1 FY27 financial results, reporting Rs. 736 Cr in revenue from operations and Rs. 91 Cr in operating EBITDA.
Syngene International Ltd reported revenue from operations of ₹736 Cr (-15.8% YoY) and a net loss of ₹9 Cr for Q1 FY27.
Mirae Asset Mutual Fund sold 861,450 shares of Syngene International Ltd via an open market transaction. The sale reduces their holding in the company.
Syngene International announced that General Counsel Surender Sharma will leave the company on July 15, 2026. He resigns by mutual consent to pursue other career opportunities.
Syngene International's board will meet on July 29, 2026, to approve Q1 FY27 financial results. An analyst call is scheduled for July 30, 2026.
B S R & Co. LLP resigned as statutory auditors of Syngene's material subsidiary, SSSL, effective July 7, 2026. The resignation aims to align auditors across the group.
Syngene disclosed a tax litigation update, receiving a Rs.0.86 Cr refund for AY 2014-15. The company expects no material financial impact, reducing contingent liability.
Syngene International will hold its 33rd AGM on July 29, 2026, to approve financials, dividend, and director appointments. The notice includes details on remuneration for new MD & CEO.
Siddharth Mittal has been appointed as Managing Director and CEO of Syngene International. He succeeds Peter Bains effective July 1, 2026.
Syngene International Limited allotted 7,29,727 equity shares worth ₹0.73 Crore to its ESOP Trust. The issuance increases total paid-up capital to 40,36,69,147 shares.
Syngene International Limited issued a postal ballot notice to redesignate Ms. Kiran Mazumdar-Shaw as Executive Chairperson. The five-year tenure commences April 2026.
Syngene International initiated a postal ballot for appointing Ms. Kiran Mazumdar-Shaw as Executive Chairperson with ₹4 Crore annual remuneration. This leadership transition aims to align with corporate strategy.
Syngene International paid Rs. 0.04 Crore in penalties to BSE and NSE for board committee composition deviations. The company has since reconstituted the committee to ensure compliance.
Syngene International Limited announced the voluntary liquidation of its wholly owned subsidiary. The closure streamlines the company's corporate structure and has no material financial impact.
Syngene approved the voluntary liquidation of its non-operational subsidiary, SMSL. The move streamlines corporate structure without impacting consolidated financial performance.
Syngene FY26 results show muted 3% revenue growth due to 'Librela' destocking headwinds. Management indicates FY27 will be a transition year with flat revenue and mid-20s EBITDA margins.
Syngene faces a transition year in FY27 as the Librela de-stocking headwind masks underlying momentum in biologics and research services.
Syngene Q4 FY26 revenue grew 2% YoY to Rs 1,037 Cr with 29% EBITDA margin. Full year FY26 revenue reached Rs 3,739 Cr, driven by integrated CRDMO services.
Syngene reported Q4 FY26 revenue of ₹1,037 Cr (up 2% YoY) and FY26 revenue of ₹3,739 Cr (up 3% YoY). Management announced leadership transitions including a new CEO effective July 2026.
Syngene International's board recommended a final dividend of ₹1.25 per equity share for FY26. The record date is June 26, 2026, with payment expected by August 27, 2026, subject to shareholder approval at the AGM scheduled for July 29, 2026.
Syngene International Limited's board approved the appointment of Mr. Vijaya Chandru and Mr. Arun Chandavarkar as Independent Directors for three-year terms starting July 2026. Additionally, Ms. Vinita Bali was appointed as a Non-Executive Director for a one-year term. These appointments bring significant expertise in biotechnology, AI, and global business leadership to the board.
Syngene International Limited has appointed M/s. S. R. Batliboi & Associates LLP as its Statutory Auditor for a five-year term (60 months) effective July 29, 2026. The appointment was approved during a board meeting on April 29, 2026.
Syngene International announced an updated list of KMPs authorized to determine event materiality. Effective July 01, 2026, Mr. Siddharth Mittal will succeed Mr. Peter Bains as Managing Director and CEO. Mr. Deepak Jain (CFO) and Mr. Chethan Yogesh (CS) remain authorized alongside the new CEO.